BRIEF published on 08/06/2026 at 08:05, 27 days 4 hours ago Pentixapharm publie ses résultats du deuxième trimestre et du premier semestre 2026 et fait progresser son programme de phase 3. Résultats Financiers Procédure Accélérée De La FDA Pentixapharm Pipeline En Oncologie Phase 3 PANDA
BRIEF published on 08/06/2026 at 08:05, 27 days 4 hours ago Pentixapharm Reports Q2 and H1 2026 Results and Advances Phase 3 Program Financial Results Oncology Pipeline FDA Fast Track Pentixapharm Phase 3 PANDA
PRESS RELEASE published on 08/06/2026 at 08:00, 27 days 4 hours ago Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program Pentixapharm Holding AG reports financial results for second quarter and first half of 2026, advancing Phase 3 Panda Program in oncology and cardiovascular sectors Financial Results Oncology Phase 3 Pentixapharm PANDA Program
BRIEF published on 07/31/2026 at 09:05, 1 month 2 days ago Pentixapharm Holding AG Advances with PentixaFor in Phase 3 Capital Raise Phase 3 PentixaFor Radiopharma PANDA Study
BRIEF published on 07/31/2026 at 09:05, 1 month 2 days ago Pentixapharm Holding AG fait progresser le PentixaFor en phase 3 Phase 3 Levée De Capitaux PentixaPour Radiopharma Étude PANDA
PRESS RELEASE published on 07/31/2026 at 09:00, 1 month 2 days ago Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY Research update: Pentixapharm Holding AG positioned for Phase 3 with strong financing secured for PentixaFor diagnostic agent. Potential commercial partnering in 2027. Target price EUR 7.20 Financing Phase 3 Pentixapharm Commercial Partnering Diagnostic Agent
BRIEF published on 07/27/2026 at 20:55, 1 month 5 days ago Pentixapharm Raises EUR 20.4 Million Through Capital Increase Capital Increase FDA Fast Track Pentixapharm [68Ga]Ga-PentixaFor PANDA Phase 3
BRIEF published on 07/27/2026 at 20:55, 1 month 5 days ago Pentixapharm lève 20,4 millions d'euros par augmentation de capital Augmentation De Capital Procédure Accélérée De La FDA Pentixapharm [68Ga]Ga-PentixaPour PANDA Phase 3
PRESS RELEASE published on 07/27/2026 at 20:50, 1 month 5 days ago Pentixapharm Completes Capital Increase – New Shares Placed in Full Pentixapharm completes capital increase, raising EUR 20.4 million for PANDA Phase 3 activities and U.S. expansion after FDA milestones Capital Increase U.S. Expansion Pentixapharm PANDA Phase 3 FDA Milestones
BRIEF published on 07/27/2026 at 20:45, 1 month 5 days ago Pentixapharm lève 20,4 millions d'euros grâce à une offre sursouscrite Augmentation De Capital Développement Clinique Sursouscription Expansion Américaine Plateforme Théranostique
Published on 09/01/2026 at 23:05, 13 hours 8 minutes ago Aton Announces US$30M Credit Facility with OU Moonrider
Published on 09/01/2026 at 22:30, 13 hours 43 minutes ago Algo Grande Copper Closes Oversubscribed Private Placement for $4.786 Million
Published on 09/01/2026 at 22:15, 13 hours 58 minutes ago NuRAN Wireless Announces Plans to Voluntarily Delist from the Canadian Securities Exchange
Published on 09/01/2026 at 16:10, 20 hours 3 minutes ago Sparton Signs Definitive Morrison Silver Mine Option and Joint Venture Agreement with Glen Eagle; Appoints Vice President, Corporate Development
Published on 09/02/2026 at 11:42, 30 minutes ago Prof. Dr. Michael A. Rübhausen Joins the Medical Advisory Board of Viromed Medical AG
Published on 09/02/2026 at 11:30, 42 minutes ago Tolochenaz accueille un nouveau carport photovoltaïque d'envergure réalisé par Romande Energie
Published on 09/02/2026 at 11:05, 1 hour 7 minutes ago Industry Leaders Outline the Future of Energy Independence for European Business in The Economist Panel Ahead of IFA 2026
Published on 09/02/2026 at 10:54, 1 hour 18 minutes ago Rixos Hotels Egypt Celebrates Seven Prestigious Wins at the World Travel Awards Africa 2026
Published on 09/02/2026 at 10:15, 1 hour 57 minutes ago Skyven Arcturus Heat Pump Achieves COP of 8.0, Marking A New Level of Industrial Steam Efficiency
Published on 09/02/2026 at 11:09, 1 hour 3 minutes ago Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Published on 09/02/2026 at 07:43, 4 hours 29 minutes ago Accor launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2032 for a nominal amount of €380 million and a concurrent partial repurchase offer with respect to its outstanding OCEANEs due 2027 by
Published on 09/02/2026 at 07:43, 4 hours 29 minutes ago Accor lance une émission d’obligations à option de conversion en actions nouvelles et/ou d’échange en actions existantes (OCEANEs) à échéance 2032 pour un montant nominal de 380 millions d’euros et une offre concomitante de rachat partiel de s
Published on 09/01/2026 at 19:00, 17 hours 13 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 09/01/2026 at 19:00, 17 hours 13 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
